{
  "study_metadata": {
    "design": "RCT|randomized|double-blind",
    "species": "Homo sapiens",
    "n_total": 40,
    "country": "Germany",
    "setting": "outpatient",
    "population": "patients with mild cognitive impairment",
    "inclusion_key": "MCI diagnosis per Mayo criteria",
    "exclusion_key": "MMSE<24, severe untreated medical, neurological, psychiatric diseases, brain pathologies, non-right-handedness, non-fluent German, BMI<18 or >35",
    "mean_age": null,
    "female_pct": 52.5,
    "diabetes_status": null,
    "primary_outcome": "HbA1c"
  },
  "intervention": {
    "agent": "resveratrol",
    "form": "capsule",
    "dose_mg_per_day": 200,
    "duration_weeks": 26,
    "cointerventions": "350 mg quercetin"
  },
  "comparison": {
    "type": "placebo",
    "description": "1,015 mg olive oil"
  },
  "arms": [
    {
      "name": "resveratrol",
      "n": 18,
      "dose_mg_per_day": 200,
      "duration_weeks": 26
    },
    {
      "name": "placebo",
      "n": 22,
      "dose_mg_per_day": 0,
      "duration_weeks": 26
    }
  ],
  "outcomes_raw": [
    {
      "name": "HbA1c",
      "timepoint_weeks": 26,
      "arm_name": "resveratrol",
      "baseline_mean": null,
      "baseline_sd": null,
      "followup_mean": null,
      "followup_sd": null,
      "change_mean": null,
      "change_sd": null,
      "units": "%",
      "notes": "lower HbA1c with moderate effect size"
    }
  ],
  "effects_by_outcome": [
    {
      "name": "HbA1c",
      "type": "SMD",
      "timepoint_weeks": 26,
      "estimate": 0.66,
      "ci_low": null,
      "ci_high": null,
      "p_value": 0.059,
      "adjusted": false,
      "model_notes": "Cohen’s d = 0.66, ANOVARM p = 0.059"
    }
  ],
  "risk_of_bias": {
    "randomization_process": null,
    "deviations_from_intended": null,
    "missing_outcome_data": null,
    "measurement_of_outcome": null,
    "selection_of_reported_result": null,
    "overall": null
  },
  "effect": {
    "type": "SMD",
    "estimate": 0.66,
    "ci_low": null,
    "ci_high": null,
    "p_value": 0.059
  },
  "where_found": [
    {
      "section": "abstract",
      "page": null
    },
    {
      "section": "methods",
      "page": null
    },
    {
      "section": "results",
      "page": null
    }
  ],
  "evidence": [
    {
      "section": "abstract",
      "page": null,
      "snippet": "resveratrol (200 mg/d; n = 18) or placebo (1,015 mg/d olive oil; n = 22) intake."
    },
    {
      "section": "results",
      "page": null,
      "snippet": "lower glycated hemoglobin A1c concentration with a moderate effect size (ANOVARM p = 0.059, Cohen’s d = 0.66)"
    }
  ],
  "missing_fields": [
    "study_metadata.mean_age",
    "study_metadata.diabetes_status"
  ],
  "confidence": 0.8,
  "comment": "Effect size reported but no raw means; data limited.",
  "comment_detailed": "I searched the abstract, methods, and results for study design, participant numbers, intervention details, and outcome data. The study is a randomized, double-blind trial with 40 MCI patients (18 resveratrol, 22 placebo) in Germany, 26 weeks duration, 200 mg resveratrol capsules plus quercetin. Glycated hemoglobin A1c was the primary glycemic outcome; the paper reports a moderate effect size (Cohen’s d = 0.66, p = 0.059) but does not provide baseline or follow-up means or SDs. Therefore, mean age and diabetes status are unknown, and raw outcome statistics are missing. Full tables or supplementary data would provide the necessary numeric values for a precise effect estimate. Confidence is moderate (0.8) due to the clear reporting of design and effect size but lack of raw data."
}